Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has been given a consensus rating of “Buy” by the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $43.40.

Several research firms have recently commented on DCPH. Nomura began coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set a “buy” rating and a $57.00 price target for the company. Piper Jaffray Companies began coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set an “overweight” rating and a $35.00 price target for the company. BidaskClub upgraded Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, January 9th. Zacks Investment Research lowered Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, January 8th. Finally, JMP Securities began coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set an “outperform” rating and a $38.00 price target for the company.

Deciphera Pharmaceuticals (DCPH) traded up $1.43 on Friday, hitting $27.47. The stock had a trading volume of 173,942 shares, compared to its average volume of 184,508. Deciphera Pharmaceuticals has a 1-year low of $15.15 and a 1-year high of $27.53.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Tuesday, November 14th. The company reported ($5.85) EPS for the quarter, missing the consensus estimate of ($0.55) by ($5.30). equities research analysts predict that Deciphera Pharmaceuticals will post -2.91 EPS for the current year.

Large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new position in Deciphera Pharmaceuticals in the third quarter valued at $143,000. FNY Managed Accounts LLC purchased a new position in Deciphera Pharmaceuticals in the third quarter valued at $153,000. Schwab Charles Investment Management Inc. purchased a new position in Deciphera Pharmaceuticals in the fourth quarter valued at $636,000. Pura Vida Investments LLC purchased a new position in Deciphera Pharmaceuticals in the third quarter valued at $1,329,000. Finally, Sphera Funds Management LTD. purchased a new position in Deciphera Pharmaceuticals in the third quarter valued at $1,424,000. Hedge funds and other institutional investors own 43.94% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://theolympiareport.com/2018/01/20/deciphera-pharmaceuticals-inc-dcph-receives-consensus-recommendation-of-buy-from-analysts.html.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.